Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration

American Journal of Nephrology

Volumn 26, Issue 6, 2007, Pages 562-570

  Navarro, Juan F ^a,b   Milena, Francisco J ^a   Mora, Carmen ^a,b   León, Candelaria ^a   García, Javier ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b CSIC   (Spain)

Author keywords

Angiotensin II; Diabetic nephropathy; Enalapril; Interleukin 1; Interleukin 6; Pentoxifylline; Tumor necrosis factor

Indexed keywords

ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION; INFLAMMATION; KIDNEY CORTEX; KIDNEY MASS; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; URINARY EXCRETION; WEIGHT REDUCTION;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CYTOKINES; DIABETIC NEPHROPATHIES; GENE EXPRESSION; HEMATOLOGIC AGENTS; INTERLEUKIN-1; INTERLEUKIN-6; KIDNEY; MALE; PENTOXIFYLLINE; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846419118     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098004     Document Type: Article

References (60)

1. Chen J, Gall M, Yokoyama H, Jensen J, Deckert M, Parving HH: Raised serum sialic acid concentrations in NIDDM patients with and without diabetic nephropathy. Diabetes Care 1996;19:130-134.
2. Pickup J, Mattock M, Chusney G, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292.
3. Katsuki A, Sumida Y, Murashima S, et al: Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:859-862.
4. Pickup J, Chusney G, Thomas S, Burt D: Plasma interleukin-6, tumor necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci 2000;67:291-300.
5. Rodríguez-Morán M, Guerrero-Romero F: Increased levels of C-reactive protein in non-controlled type II diabetic subjects. J Diabetes Complications 1999;19:211-215.
6. Abdella N, Akanji A, Mojiminiyi O, Al Assoussi A, Moussa M: Relation of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti type 2 diabetic patients. Diabetes Res Clin Pract 2000;50:65-72.
7. Bruno G, Merletti F, Biggeri A, et al: Progression to overt nephropathy in type 2 diabetes. Diabetes Care 2003;26:2150-2155.
8. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner S: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000;58:1703-1710.
9. Navarro JF, Mora C, Macía M, García J: Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 1003;42:53-61.
10. Navarro J: Nefropatía diabética: ¿una cuestión de inflamación? Hipótesis del daño renal inflamatorio en la diabetes mellitus tipo 2. Nefrología 2003;23:381-389.
11. Navarro JF: Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005;20:2601-2604.
12. Mora C, Navarro JF: The role of inflammation as a pathogenic factor in the development of renal disease in diabetes. Curr Diab Rep 2005;5:399-401.
13. Mariano F, Bussolati B, Piccoli G, Camussi B: Renal vascular effects of cytokines. Blood Purif 1995;15:262-272.
14. Noronha Il, Niemir Z, Stein H, Waldherr R: Cytokines and growth factors in renal disease. Nephrol Dial Transplant 1995;10:775-786.
15. Ostendorf T, Burg M, Floege J: Cytokines and glomerular injury. Kidney Blood Press Res 1996;19:281-289.
16. Hasegawa G, Nakano K, Manabu S, et al: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991;40:1007-1012.
17. Kalantarinia K, Awas As, Siragy HM: Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 2003;64:1208-1213.
18. DiPetrillo K, Coutermarsh B, Gesek FA: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003;284:F113-F121.
19. Zatz R, Dunn Br, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacologic amelioration of glomerular capillary hypertension. J Clin Invest 1986;1925-1930.
20. Sadoshima J: Cytokine actions of angiotensin II. Circ Res 2000;86:1187-1189.
21. Suzuki Y, Ruiz-Ortega M, Egido J: Angiotensin II: a double-edged sword in inflammation. J Nephrol 2000;13(suppl 3):S101-S110.
22. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-329.
23. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, García-Bulnes G, Salas-Ramírez M, Amato D: Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 1995;43:116-121.
24. Navarro J, Mora C, Muros M, Macía M, García J: Effects of pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomised study. Am J Kidney Dis 2003;42:264-270.
25. Navarro JF, Mora C, Rivero A, et al: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 1999;33:458-463.
26. Navarro JF, Mora C, Muros M, García J: Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16:2119-2126.
27. Nielsen S, Schmitz A, Bacher T, Rehling M, Ingerslev J, Mogensen C: Transcapillary escape rate and albuminuria in type II diabetes. Effects of short-term treatment with low-molecular weight heparin. Diabetologia 1999;42:60-67.
28. Knöbl P, Schernthaner G, Schnack C, et al: Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:1045-1050.
29. Sekizuka K, Tomino Y, Sei C, et al: Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 1994;68:284-285.
30. Shikano M, Sobajima H, Yoshikawa H, et al: Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 2000;85:81-85.
31. Nakamura T, Fukui M, Ebihara I, et al: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993;42:450-456.
32. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999;42:878-886.
33. DiPetrillo K, Gesek FA: Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 2004;24:352-359.
34. Sassy-Prigent C, Heudes D, Mandet C, et al: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000;49:466-475.
35. Suzuki D, Miyazaki M, Naka R, et al: In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995;44:1233-1238.
36. Emancipator SN, Sedor JR: Cytokines and renal disease;in Kunkel SL, Remick DG (eds): Cytokines in Health and Disease: Physiology and Pathophysiology. New York, Marcel Dekker, 1992, pp 467-488.
37. Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V: Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 2001;107:217-224.
38. Bertani T, Abbate M, Zoja C, et al: Tumor necrosis factor induces glomerular damage in rabbit. Am J Pathol 1989;134:419-430.
39. Ortiz A, Gonzalez-Cuadrado S, Bustos C, et al: Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 1995;8:27-34.
40. McCarthy E, Sharma R, Sharma M, et al: TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 1998;9:433-438.
41. Brady HR: Leukocyte adhesion molecules and kidney. Kidney Int 1994;45:1285-1300.
42. Melcion C, Lachman L, Killen D, Morel-Maroger L, Stricker GE: Mesangial cells: effect of monocyte products on proliferation and matrix synthesis. Transplant Proc 1982;14:559-564.
43. 1 during diabetic renal hypertrophy. Kidney Int 1994;46:430-442.
44. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 1990;11:443-449.
45. Ruef C, Budde K, Lacy J, et al: Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 1990;38:249-257.
46. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985;82:5963-5967.
47. Dorffel Y, Latsch C, Stuhlmuller B, et al: Pre-activated peripheral blood moncytes in patients with essential hypertension. Hypertension 1999;34:113-117.
48. Hahn AW, Jonas U, Buhler FR, Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994;347:178-180.
49. Ferreri N, Escalante A, Zhao Y, An SJ, McGiff JC: Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol Renal Physiol 1998;243:F148-F155.
50. Nakamura A, Johns EF, Imaizumi A, Yanagawa Y, Kohsaka T: Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine 1999;11:759-765.
51. Moriyama T, Fujibayashi M, Fujiwara Y, et al: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995;6:95-101.
52. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002;62(suppl 82):S12-S22.
53. Peeters AC, Netea MG, Kullberg BJ, Thien T, Van Der Meer JW: The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology 1998;94:376-379.
54. Lindmark E, Siegbahn A: Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb Res 2002;108:77-84.
55. Ortiz LA, Champion HC, Lasky JA, et al: Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-κB and AP-1. Am J Physiol Lung Cell Mol Physiol 2002;282:L1209-L1221.
56. Kaneto H, Morrisey JJ, Mccracken R, Ishidoya S, Reyes AA, Klahr S: The expression of mRNA for tumor necrosis factor α increases in the obstructed kidney of rats soon after unilateral ureteral ligation. Nephrology 1996;2:161-166.
57. Schindler R, Dinarello CA, Koch KM: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995;7:526-533.
58. Gullestad L, Aukrust P, Ueland T, et al: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine production levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-2067.
59. Stenvinkel P, Anderson P, Wang T, et al: Do ACE-inhibitors suppress tumor necrosis factor-α production in advanced chronic renal failure? J Intern Med 1999;246:503-507.
60. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003;63:209-216.